We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gene Test Validated for Breast Cancer Therapy

By LabMedica International staff writers
Posted on 12 Oct 2015
Print article
Image: The Oncotype DX specimen and collection kit for Breast Cancer Recurrence Score Assay (Photo courtesy of Genomic Health).
Image: The Oncotype DX specimen and collection kit for Breast Cancer Recurrence Score Assay (Photo courtesy of Genomic Health).
A genetic test has been clinically validated in predicting which patients with early-stage breast cancer are unlikely to benefit from chemotherapy.

Many women with hormone receptor-positive breast cancers also undergo chemotherapy in order to destroy any cancer cells that many have spread beyond the breast and reduce the risk of recurrence. While some of these women may not need chemotherapy, there is currently no effective way of determining which women could safely avoid the treatment.

A large team of scientists led by those at the Montefiore Medical Center (Bronx, NY, USA) used a 21-gene expression assay on 10,273 women ages 18 to 75 who had early-stage, hormone receptor-positive breast cancer, whereby the cancer is driven by estrogen or progesterone and that did not overexpress human epidermal growth factor receptor (HER2). Prospective validation was performed with the use of archival tumor specimens from completed studies that used a prospective–retrospective design.

All the patients had an Oncotype DX Recurrence Score (Genomic Health, Redwood City, CA, USA), a reverse-transcriptase–polymerase-chain-reaction 21-gene assay performed on ribonucleic acid (RNA) extracted from formalin-fixed paraffin-embedded tissue, performed in a central laboratory. Patients with a score of 0 to 10 were assigned to receive endocrine therapy alone, and those with a score of 26 or higher were assigned to receive chemotherapy plus endocrine therapy.

A total of 1,626 of whom were eligible, which was 15.9% of the total eligible population had a recurrence score of 0 to 10 (indicating low risk), 6,897 of whom were eligible which was 67.3% of the total eligible population had a score of 11 to 25 (indicating midrange risk), and 1,730 of whom were eligible being16.9% of the total eligible population, had a score of 26 or higher (indicating high risk). The median follow-up in the low-risk cohort was 69 months. The team found that around 99% of low-risk women treated with hormone therapy alone did not experience breast cancer recurrence within five years. Furthermore, the rate of invasive disease-free survival at five years was almost 94%, while the risk of cancer returning at a distant site was less than 1%.

The authors concluded that their prospective study involving uniformly treated patients with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer supports the clinical validity of the 21-gene assay in identifying patients who may be safely spared adjuvant chemotherapy. Joseph A. Sparano, MD, the lead authors of the study, said, “The compelling results seen in this global study provide unequivocal evidence supporting the clinical utility of Oncotype DX to risk-stratify patients with early-stage breast cancer, and indicate that the findings are generalizable to everyday clinical practice.” The study was published on September 28, 2015, in the New England Journal of Medicine.

Related Links:

Montefiore Medical Center
Genomic Health 


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.